Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANI PharmaceuticalsFRA:BSFA -2.94%78 EBITDA Margin % is 27.33% as of Mar. 2026, which is 21% above its 10-year median of 22.68. GuruFocus rates FRA:BSFA with a GF Score™ of 78/100 and a GF Value™ of €85.45 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 960 Drug Manufacturers companies, ANI Pharmaceuticals ranks better than 77.71% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ANI Pharmaceuticals's EBITDA for the
three
months ended in Mar. 2026 was €56.1 Mil. ANI Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was €205.4 Mil. Therefore, ANI Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2026 was 27.33%.
ANI Pharmaceuticals (FRA:BSFA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ANI Pharmaceuticals EBITDA Margin % Related Terms
ANI Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ANI Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BSFA vs TRLV, AMLX, XERS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (FRA:BSFA) has a EBITDA Margin % of 27.33% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ANI Pharmaceuticals and its competitors. This is 21% above median its historical median of 22.68. Over the past decade, ANI Pharmaceuticals' EBITDA Margin % has ranged from 1.44 to 34.01. According to the industry distribution chart, ANI Pharmaceuticals ranks #214 out of 960 companies in the Drug Manufacturers industry, placing it in the top 22.3%.
Is ANI Pharmaceuticals' EBITDA Margin % too high?
ANI Pharmaceuticals' current EBITDA Margin % of 27.33% is 21% above median its 10-year median of 22.68. Over the past 10 years, this metric has ranged from a low of 1.44 to a high of 34.01. The Drug Manufacturers industry median EBITDA Margin % is 12.16. ANI Pharmaceuticals' value of 27.33% is 124.8% above this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #214 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ANI Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' EBITDA Margin % compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #214 out of 960 companies for EBITDA Margin %. This places ANI Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.16. ANI Pharmaceuticals' value of 27.33% is 124.8% above this benchmark. Historically, ANI Pharmaceuticals' own EBITDA Margin % has ranged from 1.44 to 34.01 over the past decade. While the company's 10-year median is 22.68 vs. the industry median of 12.16, ANI Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.16, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current EBITDA Margin % of 27.33% is 124.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ANI Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current EBITDA Margin % is 27.33%, which is 21% above median its own 10-year median of 22.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (FRA:BSFA) is currently considered Modestly Undervalued. The stock's GF Value™ is €85.45, compared to a current price of €66.00 — trading 22.8% below its estimated fair value. The current EBITDA Margin % is 27.33%, which is 21% above median its 10-year median of 22.68 and 124.8% above the Drug Manufacturers industry median of 12.16. ANI Pharmaceuticals' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ANI Pharmaceuticals (FRA:BSFA), the current EBITDA Margin % is 27.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (FRA:BSFA) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of €66.00 is trading 22.8% below its estimated GF Value™ of €85.45.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for FRA:BSFA:
EBITDA Margin %: 27.33% (21% above median its 10-year median of 22.68)
GF Value™: €85.45 vs. price of €66.00 (22.8% below fair value)
Industry Position: 124.8% above the Drug Manufacturers median (#214 of 960)
No single metric tells the full story. See the FRA:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
78GF Score
Get the complete analysis for FRA:BSFA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BSFA has been successfully added to your 
